GREY:DGCRF - Post by User
Post by
Dibah42on May 07, 2013 4:45pm
170 Views
Post# 21354698
Potential competition?
Potential competition?
Previous Articles
Our Perspectives
Prostate Cancer
Coming Soon: The Genomic Health Oncotype DX Prostate Cancer Test
Prostate cancer screenings occur in 23 million men each year, with 250,000 being diagnosed with the affliction. The biopsy says “cancer” but current diagnostic tools can’t determine how aggressive their cancer is, so most men decide to treat prostate cancer immediately. Once treated, there are serious long-term side effects, like incontinence and sexual impotence. Immediate treatment isn’t always needed. In less severe cases, patients are quick to receive immediate treatment despite the fact that only 3% are likely to have a prostate cancer recurrence. But right now a man has no way to tell if his cancer is the kind that should be treated or if he’s OK to wait for now. Genomic Health is developing a test called the Oncotype DX Prostate Cancer Test (assay). By reviewing the underlying biology of a patient’s tumor, the Oncotype DX Prostate Cancer Test can predict the aggressiveness of prostate cancer when diagnosed. Allowing a man to make an informed decision about his treatment options. Taking care of himself, his quality of life, and…giving him peace of mind.
Read more: https://bit.ly/ProstateOncotypeDX